Circulating Tumor DNA Provides a Sneak Peek into Treatment Responses in Non-Small Cell Lung Cancer

Cancer Res. 2019 Mar 15;79(6):1038-1040. doi: 10.1158/0008-5472.CAN-19-0231.


Circulating tumor DNA (ctDNA) holds great promise as a noninvasive diagnostic tool to guide treatment for patients with lung cancer. Two studies by Phallen and colleagues and Anagnostou and colleagues correlated sensitive measures of ctDNA with clinical responses to tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors, respectively, in patients with non-small cell lung cancer (NSCLC). Together, these studies further highlight the potential clinical utility of serial ctDNA monitoring in patients with NSCLC undergoing treatment with both targeted therapies and immunotherapies.See related articles by Phallen et al., p. 1204, and Anagnostou et al., p. 1214.

Publication types

  • Comment

MeSH terms

  • Carcinoma, Non-Small-Cell Lung*
  • Circulating Tumor DNA*
  • ErbB Receptors / genetics
  • Humans
  • Lung Neoplasms*
  • Mutation
  • Protein Kinase Inhibitors


  • Circulating Tumor DNA
  • Protein Kinase Inhibitors
  • ErbB Receptors